US Stock Market Move | Starbucks Corporation (SBUX.US) rose by more than 4%, with both the North American and Chinese markets showing signs of recovery. Same-store sales have increased for two consecutive quarters.
On Wednesday, Starbucks (SBUX.US) rose over 4%, to $99.76.
On Wednesday, Starbucks Corporation (SBUX.US) rose more than 4%, reaching $99.76. In terms of news, Starbucks Corporation announced that its net revenue for the first quarter of fiscal year 2026 was $9.9 billion, a 6% year-on-year increase compared to the estimated $9.65 billion. Adjusted earnings per share were $0.56, a 19% year-on-year decrease compared to the estimated $0.59. The adjusted operating profit margin was 10.1%.
Starbucks Corporation achieved a 4% global same-store sales growth in the first quarter of 2026, marking the second consecutive quarter of positive growth and surpassing Wall Street's most optimistic expectations. The performance in the North American market was the highlight of the quarter. Same-store sales in this region grew by 4%, with comparable transactions increasing by 3% - the first positive growth in eight quarters, indicating that Starbucks Corporation has successfully reversed the previous declining customer traffic trend. Of particular note is that customer traffic in the U.S. market turned positive for the first time in eight quarters, signaling that CEO Brian Niccol's "Back to Starbucks" transformation strategy is yielding substantial results.
The performance in the Chinese market was particularly impressive, with same-store sales growing by 7%, including a 5% increase in transactions and a 2% increase in average order value. This growth rate significantly surpasses the global average, indicating that Starbucks Corporation's competitiveness in this key market is recovering. The number of Starbucks stores in China reached 8,011, a 4% increase compared to the same period last year, accounting for nearly 20% of the total global store count.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


